Company news

Fate Therapeutics, Inc. news in 2026

Fate Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

November 5, 2026

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

November 3, 2026

Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026

October 26, 2026

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

October 12, 2026

Fate Therapeutics Reports New Employee Inducement Awards under Nasdaq Listing Rule 5635(4)

October 5, 2026

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

October 1, 2026

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

September 25, 2026

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026

September 16, 2026

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR - West 2026 Meeting

September 10, 2026

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

September 9, 2026

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

September 3, 2026

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

August 14, 2026

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

August 13, 2026

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - August 3, 2026

August 4, 2026

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

July 8, 2026

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

July 6, 2026

Fate Therapeutics Appoints Laura Hamill to Board of Directors

June 15, 2026

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

June 3, 2026

Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting

June 1, 2026

Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

May 21, 2026

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

May 13, 2026

Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting

May 11, 2026

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

May 5, 2026

Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

May 4, 2026

Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting

April 30, 2026

Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases

April 17, 2026

Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting

April 16, 2026

Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR...

April 15, 2026

Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences

April 9, 2026

Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference

March 3, 2026

Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

February 25, 2026

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

February 3, 2026

Decks in 2026